FDA Clearance Tracker · P110022-S027
Elecsys Anti-HBc IgM
Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Apr 24, 2019
Approved
Time to decision
180 days
Received Oct 26, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class II
The decision
- FDA number
- P110022-S027
- Device name
- Elecsys Anti-HBc IgM
- Applicant
- Roche Diagnostics Corp.
- Applicant location
- Indianapolis, IN
- Received
- Oct 26, 2018
- Decided
- Apr 24, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P110022
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for a manufacturing site for the cobas e 411 Analyzer located at Hitachi High-Technologies Corp., 1892-1, Oazategama, Omuta, Fukuoka, 836-0004 Japan
Source documents
Other decisions for Roche Diagnostics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.